NCS Multistage Holdings, Inc. Announces Second Quarter 2026 Results
Second Quarter Results Total revenues of $38.4 million, a 5% year-over-year improvement Net loss of $(4.6) million and loss per share of $(1.71), compared to net income of $0.9 million and diluted earnings per share of $0.34 in the same quarter of 2025 Adjusted EBITDA of $1.9 million, compared to $2.2 million in the same quarter of 2025 $31.3 million in cash and $7.5 million of total debt, consisting entirely of finance lease obligations, as of June 30, 2026 HOUSTON, July 30, 2026 (GLOBE...
How this was made
The 30-second read
Why it matters
Traders can reassess near-term earnings power and liquidity risk based on the reported net loss, adjusted EBITDA decline, and cash/debt position, while also factoring in deal-related expense and geographic demand variability.
Market read
A company-specific earnings release with a pending M&A overhang, showing revenue growth but continued losses and lower adjusted EBITDA margin.
What to watch
The company highlights acquisition-related SG&A tied to the Weatherford transaction and ResMetrics contribution; separating deal-related costs from core operating performance could change the interpretation of margin pressure.
Background
NCS Multistage Holdings reported Q2 2026 results and reiterated progress toward its pending combination with Weatherford, including discussion of product and services drivers.
Ticker impact
NCSM reported Q2 2026 revenue of $38.4M, net loss of $(4.6)M, and adjusted EBITDA of $1.9M, plus $31.3M cash and $7.5M lease debt.
Near-term downside bias versus prior expectations if investors focus on the net loss and lower adjusted EBITDA margin.
Revenue rose 5% YoY, but net loss widened versus prior-year net income and adjusted EBITDA declined, which typically pressures valuation multiples; however, cash balance and working capital are still substantial, partially offsetting risk.
Market effects
Oilfield services names may see read-through on demand variability by geography (U.S. tracer diagnostics strength versus Canada fracturing softness).
Canada weakness is attributed to project delays and customer consolidation, while U.S. growth is tied to Repeat Precision and tracer diagnostics commercialization.
International tracer diagnostics project mix in the Middle East declined year over year, suggesting uneven global project timing rather than broad-based collapse.
Counterpoint
Investors may discount the net loss as non-cash or timing-driven, and focus on cash on hand plus working capital strength and product commercialization momentum.
Key entities
- public_companyNCS Multistage Holdings, Inc.
Reported Q2 2026 financial results and liquidity position, and discussed drivers including Repeat Precision and ResMetrics.
- public_companyWeatherford International plc
Named as the counterparty in NCS’s pending merger agreement announced via an Agreement and Plan of Merger.
